Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Multiple Myeloma in the Afro-Caribbean Inner City Population: Conventional Cytogenetics and Survival

Dhvani Thakker, MD, Charles Yun, MD, Adam Goldrich, MD, Helzner Elizabeth, PhD, Daniel Fein, MS4, Evelyn O. Taiwo, MD, Jason Gonsky, MD PhD, Olcay Batuman, MD

Blood (2014) 124 (21): 5710.

https://doi.org/10.1182/blood.V124.21.5710.5710

Published: 2014

Journal Articles

Cytogenetic Profile Of Multiple Myeloma In The Inner City: Clinical Presentation and Survival

Adam Goldrich, MD, Anuja Kriplani, MD, Andriane Melanthiou, MPH, Daniel Fein, MS3, Elizabeth Helzner, PhD, Arvind Babu, PhD, Jason Gonsky, MD, PhD, Olcay Batuman, MD

Blood (2013) 122 (21): 5355.

https://doi.org/10.1182/blood.V122.21.5355.5355

Published: 2013

Journal Articles

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Bani M Azari, MD/PhD, Danielle F Joseph, PhD, Marc J Braunstein, MD/PhD, H. Uwe Klueppelberg, MD, Eric LP Smith, PhD, Sadeaqua Scott, PhD, Jonathan D Marmur, MD, Anna Babinska, PhD, Olcay Batuman, MD

Blood (2010) 116 (21): 450.

https://doi.org/10.1182/blood.V116.21.450.450

Published: 2010

Journal Articles

Genomic Analysis of Endothelial Progenitor Cells In Multiple Myeloma Reveals Aberrant Gene Pathways Common to Tumor Cells

Marc J Braunstein, Sadeaqua Scott, Eric LP Smith, Danielle F Joseph, Jason Gonsky, Ruben Carrasco, Kumar Sukhdeo, Alexei Protopopov, Kenneth C Anderson, Olcay Batuman

Blood (2010) 116 (21): 3016.

https://doi.org/10.1182/blood.V116.21.3016.3016

Published: 2010

Journal Articles

Characterization of Hemangioblastic Traits within Endothelial Progenitor Cells of Multiple Myeloma Patients

Sadeaqua S Scott, PhD, Marc J Braunstein, MD/PhD, Christopher Lange, PhD, Christopher Roman, PhD, Eric LP Smith, PhD, Danielle F Joseph, PhD,, Olcay Batuman, MD

Blood (2010) 116 (21): 2984.

https://doi.org/10.1182/blood.V116.21.2984.2984

Published: 2010

Journal Articles

Endothelial Progenitor Cells within the Bone Marrow Microenvironment of Multiple Myeloma Patients Display Stem Cell Traits.

Sadeaqua S. Scott, BS, Marc J. Braunstein, BS, Christopher Lange, PhD, Christopher Roman, PhD, Uwe Klueppelberg, MD, Olcay Batuman, MD

Blood (2009) 114 (22): 2816.

https://doi.org/10.1182/blood.V114.22.2816.2816

Published: 2009

Journal Articles

Junctional Adhesion Molecule-A/ F11 Receptor (JAM-A/ F11R) Expression in Multiple Myeloma (MM): a Candidate Biomarker of Aggressive Disease.

Bani M Azari, MD/PhD, Marc J. Braunstein, MD/PhD, H. Uwe Kluppelberg, MD, Sadeaqua S Scott, PhD, Eric LP Smith, PhD, Jonathan D. Marmur, MD, Anna Babinska, PhD, Olcay Batuman, MD

Blood (2009) 114 (22): 2830.

https://doi.org/10.1182/blood.V114.22.2830.2830

Published: 2009

Journal Articles

Targeting Hsp70 in Multiple Myeloma Induces Synergistic Cytotoxicity with Inhibitors of the Proteasome and of Hsp90

Marc J Braunstein, Craig M Scott, Shannon Behrman, Peter Walter, PhD, Peter Wipf, PhD, Eric LP Smith, PhD, Sadeaqua S Scott, BA, H. Uwe Klueppelberg, MD, Jeffrey L Brodsky, PhD, Olcay Batuman, MD

Blood (2008) 112 (11): 5160.

https://doi.org/10.1182/blood.V112.11.5160.5160

Published: 2008

Journal Articles

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers

Marc J. Braunstein, Fabien Campagne, PhD, Piali Mukherjee, Daniel Ruben Carrasco, M.D., Ph.D., Kumar Sukhdeo, Alexei Protopopov, Kenneth C Anderson, MD, Olcay Batuman, MD

Blood (2008) 112 (11): 626.

https://doi.org/10.1182/blood.V112.11.626.626

Published: 2008

Journal Articles

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

James R. Berenson, MD, Thomas Ervin, MD, Ralph V. Boccia, MD, Olcay Batuman, MD, Regina Swift, RN, Christina DiLauro Abaya, BA, Andrew P. Mazar, PhD, Gilad S. Gordon, MD, Steven D. Reich, MD, Jennifer A. Callahan, BA

Blood (2008) 112 (11): 5185.

https://doi.org/10.1182/blood.V112.11.5185.5185

Published: 2008

Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3606.

https://doi.org/10.1182/blood.V110.11.3606.3606

Published: 2007

Journal Articles

Clonotypic Bone Marrow-Derived Endothelial Progenitor Cells in Multiple Myeloma.

Marc J. Braunstein, MD, PhD, Daniel R. Carrasco, MD,PhD, David Kahn, MD, Kumar Sukhdeo, PhD, Alexei Protopopov, PhD, Yunyu Zhang, Kenneth C. Anderson, MD, Olcay Batuman, MD

Blood (2006) 108 (11): 3497.

https://doi.org/10.1182/blood.V108.11.3497.3497

Published: 2006

Journal Articles

Differential Effects of Hsp70 Inhibition within the Tumor and Microenvironment in Multiple Myeloma.

Marc J. Braunstein, MD, PhD, Na Liu, MD, Uwe Klueppelberg, MD,PhD, Craig Scott, Shannon Behrman, Can Tamucin, Peter Walter, PhD, Peter Wipf, PhD, Jeffrey Brodsky, PhD, Olcay Batuman, MD

Blood (2006) 108 (11): 5070.

https://doi.org/10.1182/blood.V108.11.5070.5070

Published: 2006

Journal Articles

Clonal Restriction in Endothelial Progenitor Cells in Patients with Multiple Myeloma.

Marc Braunstein, BS, Tayfun Özçelik, MD, Sevgi Bagislar, Varsha Vakil, Eric L.P. Smith, PhD, Olcay Batuman, MD

Blood (2005) 106 (11): 2496.

https://doi.org/10.1182/blood.V106.11.2496.2496

Published: 2005

Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Iuliana Shapira, MD, Eric Smith, PhD, Marc Braunstein, BS, David Kahn, MD, Yury Pertsovsky, Olcay Batuman, MD

Blood (2005) 106 (11): 5180.

https://doi.org/10.1182/blood.V106.11.5180.5180

Published: 2005

Journal Articles

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

Tayfun Ozcelik, MD, Varsha Vakil, Eric Smith, PhD, Marc Braunstein, Justin Maroney, Uwe Klueppelberg, MD PhD, Sevgi Bagislar, Cemaliye Akyerli, Olcay Batuman, MD

Blood (2004) 104 (11): 2357.

https://doi.org/10.1182/blood.V104.11.2357.2357

Published: 2004

Journal Articles

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Uwe Klueppelberg, MD PhD, Eric Smith, PhD, Laurie Chen, MD, Chona M. Aloba, MD, Iuliana Shapira, MD, Mehdi M. Moezi, MD, Olcay Batuman, MD

Blood (2004) 104 (11): 4932.

https://doi.org/10.1182/blood.V104.11.4932.4932

Published: 2004

NARROW

Multiple Myeloma in the Afro-Caribbean Inner City Population: Conventional Cytogenetics and Survival

Cytogenetic Profile Of Multiple Myeloma In The Inner City: Clinical Presentation and Survival

Junctional Adhesion Molecule-A/F11 Receptor (JAM-A/F11R) Is a Novel Biomarker and a Potential Treatment Target In Multiple Myeloma Tumor and Its Microvascular Milieu

Genomic Analysis of Endothelial Progenitor Cells In Multiple Myeloma Reveals Aberrant Gene Pathways Common to Tumor Cells

Characterization of Hemangioblastic Traits within Endothelial Progenitor Cells of Multiple Myeloma Patients

Endothelial Progenitor Cells within the Bone Marrow Microenvironment of Multiple Myeloma Patients Display Stem Cell Traits.

Junctional Adhesion Molecule-A/ F11 Receptor (JAM-A/ F11R) Expression in Multiple Myeloma (MM): a Candidate Biomarker of Aggressive Disease.

Targeting Hsp70 in Multiple Myeloma Induces Synergistic Cytotoxicity with Inhibitors of the Proteasome and of Hsp90

Genome-Wide Profiling of Endothelial Progenitor Cells in Multiple Myeloma: Disease-Relevant Pathways and Overlaps with Common Cancer Biomarkers

Results from the Phase I Portion of a Phase I/II Study of ATN-224 and Bortezomib for Patients with Multiple Myeloma Relapsed from or Refractory to Bortezomib

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

Clonotypic Bone Marrow-Derived Endothelial Progenitor Cells in Multiple Myeloma.

Differential Effects of Hsp70 Inhibition within the Tumor and Microenvironment in Multiple Myeloma.

Clonal Restriction in Endothelial Progenitor Cells in Patients with Multiple Myeloma.

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only